Significance of pigment epithelium-derived factor levels with angiotensin II type 1 receptor blockers in patients with successful coronary stent implantation

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 12, Issue 3, 2011, Pages 320-325

  Sugihara, Makoto ^a   Miura, Shin Ichiro ^a,b   Takamiya, Yosuke ^a   Kiya, Yoshihiro ^a   Arimura, Tadaaki ^a   Iwata, Atsushi ^a   Kawamura, Akira ^a   Nishikawa, Hiroaki ^a   Yamagishi, Sho Ichi ^c   Saku, Keijiro ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b LERNER RESEARCH INSTITUTE   (United States)

^c KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin II type 1 receptor blockers; blood pressure; pentosidine; pigment epithelium derived factor; stent implantation

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BIOLOGICAL MARKER; CLOPIDOGREL; OLMESARTAN; PENTOSIDINE; PIGMENT EPITHELIUM DERIVED FACTOR; TICLOPIDINE; VALSARTAN;

ADULT; AGED; ARTICLE; BARE METAL STENT; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; BLOOD SAMPLING; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; RESTENOSIS; THERAPY EFFECT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ARGININE; BLOOD PRESSURE; BLOOD VESSEL PROSTHESIS IMPLANTATION; CORONARY ANGIOGRAPHY; EYE PROTEINS; FEMALE; FOLLOW-UP STUDIES; HEART RATE; HUMANS; LYSINE; MALE; MIDDLE AGED; NERVE GROWTH FACTORS; SERPINS; STENTS;

EID: 80052385039     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320310391921     Document Type: Article

References (16)

1. Miura S., Saku K. and Karnik SS Molecular analysis of the structure and function of the angiotensin II type 1 receptor. Hypertens Res 2003 ; 26: 937-943. (Pubitemid 38128765)
2. Fliser D., Buchholz K. and Haller H. European Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004 ; 110: 1103-1107. (Pubitemid 39319009)
3. Graninger M., Reiter R., Drucker C., Minar E. and Jilma B. Angiotensin receptor blockade decreases markers of vascular inflammation. J Cardiovasc Pharmacol 2004 ; 44: 335-339. (Pubitemid 39129452)
4. Usui M., Egashira K., Tomita H., et al. Important role of local angiotensin II activity mediated via type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade of nitric oxide synthesis in rats. Circulation 2000 ; 101: 305-310. (Pubitemid 30054158)
5. Savchenko A., Imamura M., Ohashi R., et al. Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions. J Pathol 2008 ; 215: 48-55. (Pubitemid 351619875)
6. Sugihara M., Miura S., Takamiya Y., et al. Safety and efficacy of antihypertensive therapy with add-on angiotensin II type 1 receptor blocker after successful coronary stent implantation. Hypertens Res 2009 ; 32: 625-630.
7. Rychli K., Huber K. and Wojta J. Pigment epithelium-derived factor as a therapeutic target in cardiovascular disease. Expert Opin Ther Targets 2009 ; 13: 1295-1302.
8. Yamagishi S., Adachi H., Abe A., et al. Elevated serum levels of pigment epithelium-derived factor in the metabolic syndrome. J Clin Endocrinol Metab 2006 ; 91: 2447-2450. (Pubitemid 43855041)
9. Wang JJ, Zhang SX, Lu K., et al. Decreased expression of pigment epithelium-derived factor is involved in the pathogenesis of diabetic nephropathy. Diabetes 2005 ; 54: 243-250. (Pubitemid 40105119)
10. Yohida N., Okumura K. and Aso Y. High serum pentosidine concentrations are associated with increased arterial stiffness and thickness in patients with type 2 diabetes. Metabolism 2005 ; 54: 345-350. (Pubitemid 40250094)
11. Peters S., Gotting B., Trummel M., et al. Valsartan for prevention of restenosis after stenting of type B2/C lesions: the VAL-PREST trial. J Invasive Cardiol 2001 ; 13: 93-97. (Pubitemid 33761992)
12. Monacelli F., Poggi A., Stolace D., et al. Effects of valsartan therapy on protein glycoxidation. Metabolism 2006 ; 55: 1619-1624. (Pubitemid 44830135)
13. Wang JJ, Zhang SX, Mott R., et al. Anti-inflammatory effects of pigment epithelium-derived factor in diabetic nephropathy. Am J Physiol Renal Physiol 2008 ; 294: 1166-1173.
14. Yamagishi S., Matui T. and Nakamura K. Atheroprotective properties of pigment epithelium-derived factor in cardiometabolic disorders. Curr Pharm 2009 ; 15: 1027-1033.
15. Kilhovd BK, Berg TJ, Birkeland KI, Thorsby P. and Hanssen KF Serum levels of advanced glycation end products in diabetic and coronary heart disease. Diabetic Care 1999 ; 22: 1543-1548. (Pubitemid 29418253)
16. Yamagishi S., Nakamura K., Ueda S., et al. PEDF blocks angiotensin II signaling in endothelial cells via suppression of NADPH oxidase: a novel anti-oxidative mechanism of PEDF. Cell Tissue Res 2005 ; 320: 437-445. (Pubitemid 40884145)